跳到正文
原文
Adam Feuerstein ✡️· @adamfeuerstein · X·· 2026-10-15精选AI 评分75
AI 导读

FDA批准ImmunityBio的Anktiva用于治疗更常见的乳头状非肌层浸润性膀胱癌,该批准基于单臂研究,逆转了该机构此前的监管标准。作者认为这对ImmunityBio只是部分胜利,因为新标准将广泛适用;强生研发负责人John Reed在财报电话会上称FDA已邀请其就Inlexzo提交该人群的标签扩展申请,Inlexzo第三季度销售额超过9000万美元。

推荐理由

FDA以单臂研究批准Anktiva并改变审评标准,读者可据此观察这一标准如何外溢到其他膀胱癌药物。

正文

Yesterday, the FDA approved the $IBRX drug Anktiva to treat the more common "papillary" type of non-muscle invasive bladder cancer.

The approval was based on a single arm study, reversing the agency's prior regulatory standard.

A victory for ImmunityBio and @DrPatrick ? Maybe half.

The new FDA standard for papillary NMIBC will now be broadly applied. Did anyone listen to the $JNJ earnings call on Tuesday? Here's R&D chief John Reed, speaking about its bladder cancer drug, Inlexzo:

"The FDA has invited us to submit for an expansion of our label into that population."

Inlexzo sales in Q3 were "north of $90 million," J&J said.

来源:Adam Feuerstein ✡️ · x.com